<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The authors conducted a prospective study of neurodegenerative and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> in Belgium </plain></SENT>
<SENT sid="1" pm="."><plain>Strict diagnostic inclusion criteria were used to include well defined patients and controls </plain></SENT>
<SENT sid="2" pm="."><plain>The results of <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> E (APOE) genotype effect on risk and clinical characteristics are presented </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: APOE genotyping was performed in patients with probable <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) (n=504), <z:hpo ids='HP_0002145'>frontotemporal dementia</z:hpo> (FTD) (n=47), vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) (n=152), mixed <z:hpo ids='HP_0000726'>dementia</z:hpo> (n=132), mild <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> (MCI) (n=44), <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>) (n=30), <z:hpo ids='HP_0000726'>dementia</z:hpo> with <z:hpo ids='HP_0100315'>Lewy bodies</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>) (n=17), and multisystem <z:mpath ids='MPATH_127'>atrophy</z:mpath> (MSA)/<z:e sem="disease" ids="C0038868" disease_type="Disease or Syndrome" abbrv="PSNP1">progressive supranuclear palsy</z:e> (PSP) (n=12) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The APOE allele frequencies of this Belgian control population (epsilon 2: 6.9%; epsilon 3: 76.2%; epsilon 4: 16.9%) did not differ from those reported for other white populations </plain></SENT>
<SENT sid="5" pm="."><plain>AD, MCI, and mixed <z:hpo ids='HP_0000726'>dementia</z:hpo> patients had higher APOE epsilon 4 (32.9%, 38.6%, and 28.4% respectively) and lower APOE epsilon 3 (62.2%, 53.4%, and 66.3%) frequencies compared with controls, whereas only AD and mixed <z:hpo ids='HP_0000726'>dementia</z:hpo> patients had lower APOE epsilon 2 frequencies (4.9% and 5.3%) </plain></SENT>
<SENT sid="6" pm="."><plain>Apart from a borderline significant different distribution of APOE allele frequencies in VaD patients compared with controls, no other differences were detected </plain></SENT>
<SENT sid="7" pm="."><plain>The influence of APOE epsilon 4 on clinical features of <z:hpo ids='HP_0000726'>dementia</z:hpo> was limited to lower age at <z:hpo ids='HP_0003674'>onset</z:hpo> in AD patients and a less pronounced negative correlation between age at <z:hpo ids='HP_0003674'>onset</z:hpo> and number of epsilon 4 alleles in MCI and mixed <z:hpo ids='HP_0000726'>dementia</z:hpo> patients </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: This study confirmed the risk association between APOE epsilon 4 and AD </plain></SENT>
<SENT sid="9" pm="."><plain>The observation that APOE epsilon 4 is associated with mixed <z:hpo ids='HP_0000726'>dementia</z:hpo> reflected the role of AD in the aetiopathogenesis of this condition </plain></SENT>
<SENT sid="10" pm="."><plain>Although MCI is an aetiologically <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> syndrome, the increased APOE epsilon 4 frequencies indicated that a large proportion of the MCI patients included in the study might be predisposed to develop AD </plain></SENT>
</text></document>